- Pharmaceutical companies
- Celgene
Celgene
| Type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 1986 (1986) |
| Founder | Sol J. Barer |
| Headquarters | Summit, New Jersey, U.S. |
| Key people | Robert J. Hugin (Executive Chairman) Mark Alles (CEO) |
| Products | Revlimid Abraxane Pomalyst/Imnovid Thalomid Idhifa |
| Revenue | |
| Net income | |
| Total assets | |
| Total equity | |
| Number of employees | 8,852 (2018) |
| Parent | Bristol Myers Squibb |
| Website | www.bms.com |
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
For detailed contact information visit location pages below.
Celgene's locations around the world
Clinical Trials sponsored by Celgene
-
CelgeneCelgene CorporationCompletedGlioma | Solid Tumor | Angioimmunoblastic T-cell Lymphoma | Chondrosarcoma | Intrahepatic CholangiocarcinomaUnited States, France
-
CelgeneCelgene CorporationTerminatedAdvanced Solid TumorsUnited States
-
CelgeneCelgene CorporationCompletedMultiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in RelapseUnited States, Australia
-
Celgene CorporationCompletedMultiple MyelomaUnited States, Spain, Australia, Canada, United Kingdom, Italy, Switzerland, Bulgaria, Poland, Ukraine, Belgium, Germany, Hungary, Ireland, Israel, Russian Federation
-
Celgene CorporationTerminated
-
Celgene CorporationCompletedRelapsed or Refractory Multiple MyelomaGermany
-
Celgene CorporationTerminatedDiffuse Large B-cell LymphomaUnited States, Canada, Australia
-
Celgene CorporationCompletedComplex Regional Pain Syndrome (RSD)United States
-
Celgene CorporationCompletedGlioblastoma | Malignant GliomasUnited States
-
CelgeneCelgene CorporationCompletedLymphoma | CancerUnited States, United Kingdom